1. Amgen's dividend growth is strong with a 2.8% yield and consistent hikes since 2011, providing reliable income and a healthy payout ratio; 2. A robust R&D pipeline in obesity, cardiovascular, and oncology, along with strong financials, positions Amgen for long-term growth and stability; 3. Despite underperforming the S&P 500, Amgen's focus on high-growth areas and promising new drugs offers a compelling growth narrative; 4. Trading at a reasonable valuation, Amgen's combination of consistent dividend growth and promising R&D developments makes it a worthy pick for conservative investors.